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Abstract 
Adenosine is a nucleoside that is particularly interesting to many scientific and clinical 
communities as it has important physiological and pathophysiological roles in the kidney.  
The distribution of adenosine receptors has only recently been elucidated; therefore it is 
likely that more biological roles of this nucleoside will be unveiled in the near future.  
Since the discovery of the involvement of adenosine in renal vasoconstriction and 
regulation of local renin production, further evidence has shown that adenosine signaling is 
also involved in the tubuloglomerular feedback mechanism, sodium reabsorption and the 
adaptive response to acute insults, such as ischemia. However, the most interesting finding 
was the increased adenosine levels in chronic kidney diseases such as diabetic nephropathy 
and also in non-diabetic animal models of renal fibrosis. When adenosine is chronically 
increased its signaling via the adenosine receptors may change, switching to a state that 
induces renal damage and produces phenotypic changes in resident cells. This review 
discusses the physiological and pathophysiological roles of adenosine and pays special 
attention to the mechanisms associated with switching homeostatic nucleoside levels to 
increased adenosine production in kidneys affected by CKD. 
Keywords: Chronic Kidney Disease; Adenosine Receptors; Nucleoside Transporters; 
Renal Fibrosis. 
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1. Introduction 
The adenosine nucleoside was identified as a bioactive molecule when Drury and Szent-
Györgyi (1929) discovered its influence in several physiological tasks such as 
cardiovascular function. The role of adenosine in renal physiology was first studied in the 
60´s when it was discovered that infusion of adenosine to the renal artery increased renal 
vascular resistance (Hashimoto and Kumakura, 1965; Haddy and Scott, 1968). This 
evidence promptly lead to the notion that adenosine decreases glomerular filtration, and 
then its role on sodium excretion rates and influence on renin activity were characterized 
(Tagawa and Vander, 1970; Osswald, 1975). 
Since the competitive nature of methylxanthines, including caffeine and theophylline, on 
the effects of adenosine in the heart (De Gubareff and Sleator, 1965) and brain (Sattin and 
Rall, 1970) were recognized, it was convincingly supported the idea that specific receptors 
for this nucleoside may exists (Cobbin et al., 1974). In the 90’s adenosine receptors from 
human and mammals were cloned. There are four different adenosine receptors, named A1, 
A2A, A2B, and A3, belonging to the receptor family with seven transmembrane domains, 
coupled to diverse types of G proteins, which exhibit different affinities to their adenosine 
ligand (Fredholm et al. 2001, 2011). Since their identification, multiple studies have 
searched for the presence of adenosine receptors in renal cells, using diverse experimental 
approaches, to correlate their localization with a physiological function (see Table I). 
Knockout animal models of these receptors have recently been generated, some of which 
have been a valuable tool for evaluating the effects of adenosine in the kidney (Sun et al. 
2001; Tak et al. 2014; Yang et al. 2016). Therefore, discovering the biochemical 
mechanisms that control adenosine extracellular availability and influence its biological 
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activity has been a daunting task. A series of ectoenzymes that metabolize precursor 
nucleotides to generate adenosine were also identified. Additionally, nucleoside transporter 
systems which control adenosine flux through the plasmatic membrane, involved in 
presenting the ligand to activate signalling via adenosine receptors, were also characterized 
(Quezada et al. 2013; Shirley et al. 2009). 
In this review we will discuss the contribution of adenosine and its receptors to 
fundamental renal physiological functions. We will also present evidence that supports the 
role on adenosine in renal fibrosis progression, which is considered a common event during 
chronic kidney disease (CKD), independent of its origin, and which strongly correlates with 
progressive loss of renal function. 
2. Adenosine metabolism in the kidney 
The biological effects of adenosine are mediated by signaling via adenosine receptors in the 
plasma membrane. Adenosine is the main, if not exclusive, agonist of these receptors; 
therefore its bioactivity is dependent on its extracellular availability (Fredholm et al. 2011). 
Inosine could act as a partial agonist of the A3AR subtype (Jin et al. 1997; Fredholm et al. 
2001), but since this nucleoside is a catabolic product of adenosine it reinforces the 
physiological importance of adenosine generation at the tissular level. Adenosine is 
generated from intracellular synthetic pathways or in the extracellular compartment by 
catabolism of precursor nucleotides such as ATP or cyclic AMP (cAMP) (Jackson and 
Dubey, 2004; Vallon et al. 2009). The intracellular pathway of adenosine synthesis is 
mediated either by an intracellular 5’-nucleotidase, which dephosphorylates AMP 
(Schubert et al. 1979; Zimmermann et al. 1998), or hydrolysis of S-adenosyl-homocysteine 
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(Broch and Ueland, 1980). Intracellularly generated adenosine may be transported into the 
extracellular space mainly via specific bi-directional transporters by facilitated diffusion 
(Pastor-Anglada and Pérez-Torras, 2015). Some cells have an increased potential to release 
adenosine into the extracellular milleu (Fredholm et al. 1994; Parkinson et al. 2005), 
however, there is no evidence of renal cells having this potential. This is likely due to the 
fact that extracellular catabolism of precursor nucleotides is the major source of adenosine 
production at renal compartments during physiological or pathological responses. 
Classical examples of adenosine generation from nucleotide precursors have been described 
along the nephron. ATP may be hydrolyzed enzymatically by ectonucleoside triphosphate 
diphosphohydrolase (CD39) generating AMP. AMP then converts into adenosine via the 
enzyme 5'-ectonucleotidase (CD73) (Vallon et al. 2009). In addition, alkaline phosphatase 
at the proximal tubule may also generate adenosine even though it has a high Km for 
adenine nucleotides (Oyarzún et al. 2015). Prostatic acid phosphatase (PAP) is another 
enzyme that catalyzes AMP hydrolysis, however, its distribution and physiological roles in 
the kidney are poorly understood (Lam et al. 1989), although it has been attributed a role in 
renal carcinogenesis (Shibata et al. 2003). The types and distribution of ectonucleotidases 
along the rat nephron and murine renal substructures was previously described (Kishore et 
al. 2005; Shirley et al. 2009) and therefore is not included within this review.  
In the rat glomerulus, the basal ATP release rate is approximately 0.30 pmol/min/1000 
glomeruli (Karczewska et al. 2007). Exogenous ATP was rapidly degraded by the 
glomeruli suspension, with a t1/2 decay of 2 min, indicating that efficient extracellular 
catabolism occurs at this compartment, an observation that is reinforced by the abundance 
of nucleotidases in the glomerulus (Kishore et al. 2005; Shirley et al. 2009). Addition of 
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ARL67156, an ecto-ATPase activity inhibitor, to the glomeruli suspension caused 
extracellular ATP to gradually increase. Following ATP hydrolysis the AMP concentration 
was higher than other hydrolysis derived products. Under normal conditions, glomeruli 
hydrolyze AMP to adenosine, although less efficiently than ATP to ADP and AMP 
(Karczewska et al. 2007), which allows adenosine signaling in glomerular cells or 
downstream signaling throughout the nephron.  
Another example of adenosine signaling dependent on extracellular ATP hydrolysis is 
paracrine communication between macula densa cells and afferent arterioles. ATP released 
from cells in the macula densa is metabolized to adenosine in the extracellular space and 
mediates the vasocontractile response of afferent arterioles. Despite the fact that P2 
purinergic receptors are widely distributed throughout the kidney (Burnstock et al. 2014), 
only a minor role in afferent arteriolar vasoconstriction has been perceived (Schnermann, 
2011; 2015), indicating that metabolic imbalance towards the degradation of released ATP 
is relevant to the production of the vasoactive effector adenosine. Indeed, the paracrine 
pathway and afferent arteriolar vasoconstriction was deficient in mice that do not express 
5'-ectonucleotidase (Castrop et al. 2004). 
In addition, adenosine may also be generated from extracellular cAMP degradation by an 
ecto-AMP phosphodiesterase, followed by AMP metabolism to adenosine by 5'-
ectonucleotidase (Jackson and Dubey, 2004). This pathway for extracellular adenosine 
formation was demonstrated in in vivo proximal tubules, collecting tubules and in primary 
cultures of cells derived from these tubules (Jackson et al. 2003, 2006). Intriguingly, renal 
epithelial cells along the nephron can extracellularly metabolize non-conventional 2',3'-
cAMP to 2'-AMP and 3'-AMP and further efficiently metabolize extracellular 2'-AMP and 
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3'-AMP to adenosine using non classical phosphodiesterases and ecto-5'-nucleotidase 
(Jackson and Gillespie, 2013). Since 2', 3'-cAMP may be released from cells upon injury, 
further research is needed to identify if there is a significant difference in 2', 3'-cAMP 
levels between the physiological and pathophysiological states.    
In addition to the rate of extracellular synthesis, research has also focused on the 
mechanism that regulates external accumulation of adenosine; which is dependent on cell 
uptake (San Martin et al. 2009). Nucleoside transport in eukaryotic cells is mediated by two 
families of structurally-unrelated membrane proteins: the Na+-independent facilitative 
equilibrative nucleoside transporters (ENTs) family and the Na+-dependent concentrative 
nucleoside transporters (CNTs) family (Hyde et al. 2001; Gray et al. 2004; Kong et al. 
2004; Baldwin et al. 2004). Each family of nucleoside transporters has several members, 
being CNT2, CNT3, ENT1, ENT2 and ENT3 capable of transporting adenosine (Pastor-
Anglada and Casado, 2006). It is supposed that nucleoside transporters are widely 
distributed throughout all cells types, due to the implications that the uptake of bases and 
nucleobases has on energetic metabolism and salvage pathways. However, it is currently 
known that nucleoside transporters are expressed in specific cell type patterns and may 
have a selective subcellular distribution (Jennings et al. 2001; Govindarajan et al. 2007). In 
fact, ENT3 (Baldwin et al. 2005) and ENT2 isoforms (Grañé-Boladeras et al. 2016) were 
involved in nucleoside transport activity in intracellular compartments. A variety of 
physiological models have shown that pharmacological inhibition of ENT1 or ENT2 at the 
plasma membrane results in increased extracellular adenosine concentration, favoring a 
specific biological effect via adenosine receptor activation (Mubagwa and Flameng, 2001; 
Ackley et al. 2003; Sonoki et al. 2003; Choi et al. 2004; Riksen et al. 2005; Carrier et al. 
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2006; Farías et al. 2006; Grenz et al. 2012; Cárdenas et al. 2013). Also, there is increasing 
evidence of the distribution and probable function of nucleoside transporters in the kidney. 
In renal epithelial cells, hCNT1, hCNT2, and hCNT3 at the apical membrane and hENT1 
and hENT2 at the basolateral membrane, apparently work together to mediate nucleoside 
reabsorption from the lumen to blood, driven by Na+ gradients (Elwi et al. 2006). 
Additional evidence suggests that the distribution of the main equilibrative nucleoside 
transporter ENT1 may be present in both apical and basolateral membranes of renal 
epithelia and extratubular locations including the glomeruli, vascular smooth muscle and 
endothelial cells (Roa et al. 2009; Damaraju et al. 2007). Thus, extensive distribution of 
ENT1 throughout the kidney indicates that this transporter plays a role in facilitating 
adenosine signaling beyond nucleoside and nucleobase solute homeostasis (Roa et al. 2009; 
Damaraju et al. 2007; Elwi et al. 2006). An overview of the mechanisms involved in 
extracellular adenosine generation linked with cellular signaling is shown in figure 1.  
3. Physiological functions of adenosine in the kidney 
The kidney is a fundamental organ for corporal homeostasis. It is organized into functional 
units known as nephrons connected to a capillary network nourished by blood, which 
participates in the process of filtration, reabsorption and excretion of solutes, and blood 
back into the circulatory system. The basic nephron function is to purify the blood of waste 
products via filtration at the glomeruli, as well as remove solutes, ions and water from the 
filtrate at the tubular level to produce urine. Additionally, the kidney has a fundamental role 
in regulating blood volume and arterial pressure. It is also involved in the glucose 
metabolism and regulation of pH, ion levels and hormone synthesis. Thus, certain renal 
cells, such as tubular epithelial cells, are recognized as polyfunctional and therefore, 
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understanding their physiology is an interesting but hard task for clinical and basic 
researchers. Over the last years there has been special interest in the generation of factors 
that can locally affect renal cell function, among those the intrarenal Renin-Angiotensin 
System (RAS) and production of other vasoactive molecules (Zhuo et al. 2013). Equally, 
conclusive background information indicates that adenosine, produced as an autacoid, and 
its interaction with other effector systems, regulates renal function (Vallón et al. 2006). It is 
involved in the regulation of afferent and efferent artery vascular tone and crosstalk with 
the renin-angiotensin system (Navar et al. 1996; Peti-Peterdi and Harris, 2010; Weihprecht 
et al. 1994). 
3.1 Involvement of adenosine in renal vascular tone regulation 
Renin is an enzyme secreted by kidney juxtaglomerular cells (JG) where it is synthesized as 
a preproenzyme that later converts into prorenin; the mature but inactive form of the 
enzyme (Urushihara and Kagami, 2016; Morales, 2010). Once activated this enzyme is key 
to the renin-angiotensin system since it is in charge of transforming angiotensinogen to 
angiotensin I (Huang et al. 2016). Therefore the amount of renin is a limiting step during 
the production of Ang II, the main RAS component that acts as a critical element to the 
regulation of blood pressure and CKD pathogenesis. Renin release by JG cells is stimulated 
by cAMP and is inhibited by an increase in intracellular calcium levels (Ortiz-Capisano et 
al. 2013) and endothelins in a calcium dependent way (Ortiz-Capisano et al. 2014). cAMP 
is a second messenger used for the transduction of intracellular signals in diverse biological 
processes, having an important role in stimulating renin gene expression. Factors that 
increase cAMP levels stimulate renin expression in JG cell cultures (Lopez and Gomez, 
2010; Gomez et al. 2009). The inhibitory effect of adenosine on renin release was 
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confirmed in dogs (Macias-Nunez et al. 1985; Arend et al. 1984), rats (Churchill and 
Bidani, 1987; Osswald et al. 1978), isolated rat kidney (Murray and Churchill, 1984, 1985), 
rat glomeruli (Skott and Baumbach, 1985) and in humans (Edlund et al. 1994). Adenosine 
produced at the macula densa inhibits renin release through activation of the A1 adenosine 
receptor in mouse JG cells (Ortiz-Capisano et al. 2013). This has also been shown in vivo; 
when adenosine was injected into the renal artery in the canine kidney, a decrease in renin 
production was observed (Deray et al. 1989). Also, A1 receptor knockout mice have a 
significantly increased renin plasmatic concentration compared to wild type mice (Schweda 
et al. 2005). Studies in JG mouse cells showed that A1 receptor activation results in a 
calcium dependent inhibition of renin release via transient receptor potential canonical 
channels (TRPC)-mediated calcium entry (Ortiz-Capisano et al. 2013). The role of the 
adenosine A2 subtype receptors in renin release is less clear. In the 80´s, studies using an A1 
receptor agonist (CHA) indicated that low concentrations were capable of inhibiting renin 
release, meanwhile elevated concentrations of CHA stimulated renin release (Churchill and 
Churchill, 1979, 1985), indicating the existence of an interaction between the agonist with 
other receptors. Later, in vivo studies in dogs showed that selective stimulation of A2 
receptors induced renin release (Miura et al. 1999). 
The afferent and efferent arterioles are an important site for autoregulation of perfusion and 
glomerular filtration rate. In general, various vasoactive substances, such as thromboxane, 
superoxide and kinins, may modulate renal vasculature tone, reactivity and resistance. 
Importantly, studies have recognized the convergence of Angiotensin II activity (Ang II) 
and adenosine in the afferent arteriole to mediate tubuloglomerular feedback (TGF) (Franco 
et al. 2009; Persson et al. 2013). TGF indicates a negative relationship between NaCl 
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concentration at the macula densa and glomerular filtration rate or glomerular capillary 
pressure (Schnermann, 2015). Ang II induces renal microvasculature constriction via the 
AT1 receptor (Harrison-Bernard et al. 2006). Meanwhile, adenosine produces different 
responses depending on the type of receptor with which it interacts; A1 receptor regulates 
contraction (nM range) and A2 receptor regulates dilation (nM range) (Lai et al. 2006a). At 
physiological concentrations Ang II increases the adenosine contractile response (Lai et al. 
2006a). Correspondingly, low concentrations of adenosine significantly increase the 
response of the afferent arteriole to Ang II (Lai et al. 2006a). Many studies have shown that 
the adenosine A1 receptor is important for the synergic interaction between adenosine and 
Ang II, however, other mechanisms can also contribute to this phenomenon (Lai et al. 
2006b; Hansen et al. 2003; Gao et al. 2011). It was recently shown that arteriolar 
contraction induced by Ang II is decreased in A1 receptor knockout mice; however 
administration of adenosine sensitizes the contractile response both in control and knockout 
mice (Gao et al. 2015). On the other hand, it was shown that temporary injection of Ang II 
elevates interstitial and tissue levels of adenosine (Franco et al. 2008). To explain this 
effect, it is assumed that vasoconstriction induced by Ang II leads to ischemia, producing 
de novo formation of adenosine. This is also explained by the fact that Ang II induces a 
significant decrease in adenosine deaminase (ADA) activity, as well as a decrease in 
mRNA and protein levels of this enzyme, which catabolize adenosine to inosine. In turn, 
increased adenosine concentration also directs downregulation of the A2A receptor, 
allowing the adenosine vasoconstrictor effect to be preferentially regulated through A1 
receptor activation (Franco et al. 2008). In humans and animals with CKD, the circulating 
levels of Ang II are induced (Urushihara and Kagami, 2016). Interestingly, Dai et al. (2011) 
showed that renal fibrosis progression, in a model of Ang II infusion, was concurrent with 
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increased adenosine levels and could be blocked by using an adenosine A2B receptor 
antagonist, highlighting the interaction between adenosine signalling and the RAS system. 
Nitric oxide (NO) is another vasoactive molecule relevant to renal function. Bioactivity of 
adenosine receptors produces different effects on NO levels, generating diverse results at 
the vascular beds. Activation of the A1 receptor regulates renal vasoconstriction through 
both decreased NO generation and increased production of vasoconstrictor compounds 
from the COX (cyclooxygenases) pathway of arachidonic acid metabolism (Barrett and 
Droppleman, 1993; Walkowska et al. 2007). On the other hand, activation of the A2A and 
A2B receptors produces vasodilator effects through stimulation of NO production (El-
Gowelli et al. 2013; Carroll et al. 2006). While A2A and A2B receptors are expressed in 
afferent arterioles, studies indicate that the vasodilator actions occur essentially by 
activation of the A2B receptor (Feng and Navar, 2010). However, Carlström and colleagues 
showed that stimulation of the A2A receptor attenuated tubuloglomerular feedback 
responses by stimulating endothelial nitric oxide synthase (eNOS), presumably at the 
afferent arteriole (Carlstrom et al. 2011). It is also known that intravenous administration of 
adenosine causes vasodilatation mediated by the activation of the A2A receptor/NO axis, 
since dilatation induced by adenosine was abolished in eNOS knockout mice and in wild 
type mice treated with l-NAME, suggesting that eNOS is a source of NO that mediates the 
vascular effects of A2A activation (Hansen et al. 2005). The potential role of the adenosine 
A2A receptor in mediating eNOS activation and modulating vascular tone has been shown 
in rat aorta, carotid artery (Ray and Marshall, 2006; Teng et al. 2008) and human fetal 
endothelium, which is named the ALANO pathway in the latter system (San Martín and 
Sobrevia, 2006).  
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Lastly, studies on the effects of A3 receptor activation on vascular control at the renal beds 
are scarce. Evidence indicates that activation of the A3 receptor dilated the norepinephrine-
preconstricted afferent arterioles and blunted the vasoconstrictive effect of adenosine A1 
receptor activation (Lu et al. 2015). The effects of A3 receptor activation in other vascular 
niches are contradictory to date (Hinschen et al. 2003; Ansari et al. 2007). 
3.2 Roles of adenosine in ions balance 
Many studies have characterized the role of adenosine in absorption and excretion of ions 
in the tubular renal system. The first correlation between adenosine and balance of the Na+ 
and Cl- secretory and absorptive pathways in the kidney come from Siragy and Linden, 
(1996) who described that increased NaCl intake could modulate adenosine production in 
the kidney. In experiments performed with rats maintained with a low salt diet (0.15%), 
adenosine concentration significantly decreased (23.3 ± 3 nM cortex; 55.5 ± 5 nM 
medulla). Meanwhile when salt intake increased (4%), adenosine renal production also 
increased (418 ± 43 nM cortex; 1040 ± 37 nM medulla), being higher in the medulla than in 
the renal cortex (Siragy and Linden, 1996) and indicating that NaCl concentration and 
adenosine production in the kidney is tightly regulated, especially in the medullar zone. As 
described above, TGF is regulated by adenosine through the A1 and A2A adenosine 
receptors. This mechanism directly relates tubular NaCl concentration in the ascending 
limb of Henle's loop and afferent arteriolar tone (Hansen and Schnermann, 2003; Huang et 
al. 2006). The best characterized adenosine function in solute reabsorption in the kidney is 
related to tubular Na+ reabsorption. The A1 adenosine receptor regulates Na+ reabsorption 
in the proximal tubule (responsible for reabsorbing 60-70% of filtrated Na+) effecting the 
activity of multiple transporter systems, including the Na+/H+ exchanger-3 (NHE3), the 
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Na+/PO4- cotransporter and Na+-dependent glucose transporter (SGLT) (Welch, 2015). It 
was shown that administration of selective A1 receptor antagonists cause diuresis and 
natriuresis, reaffirming that this receptor mediates sodium and water reabsorption (Vallon 
et al. 2009). Also, the use of an antagonist or deletion of the A1 receptor decreased 
hypertensive outcomes in different animal models (Welch, 2015). Other studies have 
demonstrated a relationship between salt intake and adenosine A1 receptor expression. 
Increased salt intake in rats decreased adenosine A1 receptor expression in the collector 
duct, meanwhile in the proximal tubule, decreased salt intake increased A1 receptor 
expression thus increasing Na+ reabsorption (Siragy and Linden, 1996; Zou et al. 1999; 
Kulick et al. 2008). These changes could be part of a feedback mechanism that allows 
increased Na+ reabsorption in the proximal tubule when faced with low salt intake and high 
excretion under high salt consumption, apparently functioning through modulation of A1 
receptor expression and activity (Rajagopal and Pao, 2010; Zou et al. 1999). Although 
many researchers have shown a relation between NaCl homeostasis and regulation via 
activity of the adenosine A1 receptor in the kidney, evidence is still needed to understand 
the intracellular mechanisms that regulate this feedback. 
One proposed mechanism of NaCl homeostasis through the adenosine A2A receptor 
involves stimulation of K+ channels and Cl- secretion (Wang et al. 2011; Gu et al. 2007). 
Most potassium is reabsorbed in the proximal tubule by passive transport and solvent drag. 
25% is reabsorbed in the loop of Henle by the Na+-K+-2Cl- symporter and the remaining 
potassium reaches the distal nephron and can be reabsorbed or eliminated in the urine 
(Stone et al. 2016, Palmer, 2015). Adenosine activates K+ channels in the basolateral 
membrane of cells of the ascending limb of the Henle´s loop in the rat kidney, dependent 
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on A2A receptor activation of PKA (Gu et al. 2007). K+ channels participate in epithelial 
transport in cells from the thick ascending limb of the loop of Henle, which is responsible 
for the absorption of 20-25% of filtered Na+ (Gu et al. 2007; Hebert, 1998). The apical K+ 
channels are essential for K+ recycling, maintaining Na+/Cl-/K+ cotransporter function 
(Simon et al. 1996), meanwhile basolateral K+ channels participate in generating the 
membrane potential in the thick ascending limb of the Henle´s loop (Hebert et al. 2005). 
Thus, the A2A adenosine receptor could increase signalling through the cAMP-PKA 
pathway, activating K+ basolateral channels and leading to synchronized entrance of apical 
Cl- and basolateral exit, which indirectly increase Na+/Cl-/K+ cotransporter activity at the 
apical membrane, favouring Na+ reabsorption (Wang et al. 2011; Gu et al. 2007). The A2B 
receptor mediates a different signalling pathway to regulate NaCl secretion through the 
collecting duct when faced with excessive salt intake (Rajagopal and Pao, 2010). Studies in 
mIMCD-K2 cells (renal inner medullary collecting duct) show that adenosine activates the 
apical A2B receptor when its concentration reaches the micromolar range, stimulating Cl- 
secretion through CFTR (cystic fibrosis transmembrane conductance regulator), via a 
cAMP/PKA dependent signalling pathway (Rajagopal and Pao, 2010).  
Studies also indicate that adenosine could regulate the transport of other ions in the kidney. 
Adenosine modulates Mg2+ uptake in distal convoluted tubule cells via A1 and A2 receptors 
and a volume sensitive-like chloride conductance in the rabbit distal convoluted tubule cell 
line (DC1) (Kang et al. 2001; Rubera et al. 2001). 
To mediate these physiological tasks fine-tuned regulation of extracellular levels and 
clearance of adenosine is required. Basal extracellular adenosine levels are estimated to be 
between 30 to 200 nM (Ballarín et al. 1991). This amount is sufficient to activate some of 
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the high affinity adenosine receptors under physiological conditions and can result from 
equilibrative transport of adenosine through ENTs, balancing intracellular production with 
extracellular nucleoside generation. From this baseline level, adenosine can increase 
substantially when extracellular formation increases as a result of adenine nucleotide 
release from cells as described above. In addition, extracellular accumulation of adenosine 
may occur due to decreased cell uptake through ENTs. Both these mechanisms may have a 
role in dysregulation of adenosine levels in CKD models. Indeed, ent1-/- mice exhibit 
elevated interstitial and plasmatic adenosine levels affecting renal physiology and renal cell 
function (Li et al. 2013). 
4. Pathogenesis of Chronic kidney disease 
Chronic kidney disease (CKD) is defined by most clinical and genetic epidemiological 
studies as a condition with an estimated GFR (eGFR) of < 60 ml·min−1·1.73 m-2, 
irrespective of the presence or absence of any additional kidney damage (Levey et al. 
2005). Pathological features of CKD are inflammatory infiltration, tubular atrophy, 
capillary rarefaction, podocyte depletion and fibrosis (Duffield et al. 2013; Campanholle et 
al. 2013). CKD remains an incurable disease and it is estimated to affect 8-16% of the 
world’s population (Jha et al. 2013). Two of the most prevalent causes of CKD are 
hypertension and diabetes. CKD severely affects patient’s quality of life, their lifetime 
productivity and is a source of mortality due to cardiovascular events (Go et al. 2004). As 
diabetic and nondiabetic CKD progresses, the costs associated with patient care 
considerably increase too, due to the requirement of organ replacement therapies (Jha et al. 
2013). Patient management includes prescribing antidiabetics, antidyslipidemics and 
antihypertensives. Over the last decades, the use of RAS blockers, including angiotensin-
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converting enzyme inhibitors or angiotensin II type I receptor antagonists, affected only 
modestly CKD progression (Jha et al. 2013). Therefore, searching for new therapies and 
tools to assist in the early diagnosis of CKD continues to be a challenge.  
Among the pathogenic mechanisms involved in CKD in diabetes, the best described 
mechanism is how hyperglycemia alters renal cell functions. Hyperglycemia activates 
several protein kinase C isoforms, a step that is required for local production of growth 
factors such as the transforming growth factor-β (TGF-β) and the vascular endothelial 
growth factor (VEGF) (Ziyadeh, 2008). Also involved in this pathology are metabolic 
factors, such as advanced glycosylation end products (AGE) (Forbes et al. 2003), oxygen 
reactive species (Ha et al. 2008) and aldose reductase/polyol pathways (Dunlop, 2000). 
Further CKD of diabetic and non-diabetic origin presents common alterations to renal 
synthesis and the activity of some hemodynamic factors such as RAS (Mezzano et al. 
2003), endothelins (ETs) (Sorokin and Kohan, 2003) and a decrease in nitric oxide (NO) 
bioavailability (Nakagawa, 2009). Production of pro-inflammatory mediators, as well as 
monocytes/macrophages interstitial invasion, may also contribute to renal injury and 
fibrosis (Fornoni et al. 2008). Recently, the pathogenic role of adenosine signaling in 
mediating glomerulopathy (Quezada et al. 2013; Cárdenas et al. 2013) and renal fibrosis 
(Kretschmar et al. 2016; Roberts et al. 2014) has emerged as a new player contributing to 
CKD as discussed below. 
The fibrotic process is crucial in CKD since it generates irreversible organ scaring as a 
result of extracellular matrix (ECM) deposition in renal structures such as the capillary 
glomerular wall, arterioles, mesangial and tubule-interstitial space (Duffield, 2014; Liu, 
2005), leading to progressive loss of renal function and end stage renal disease (ESRD) 
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(Duffield, 2013). Briefly, renal fibrosis pathogenesis is commonly represented by an initial 
and repetitive tissue insult (toxic, metabolic, infectious, ischemic or immunologic) leading 
resident kidney cells, such as tubular epithelial cells and mesangial cells (Campanholle et 
al. 2013), to trigger an inflammatory processes, secreting a series of pro-inflammatory 
cytokines and chemokines such as, TNF-α, IL1-β, MCP-1, among others (Hirschberg, 
2005; Meng et al. 2014). These signaling molecules induce platelet coagulation and 
infiltration of the immune cells such as neutrophils, dendritic cells, T lymphocytes and 
monocytes/macrophages in the glomeruli and interstitium (Duffield, 2013).  Inflammatory 
cells produce harmful molecules, such as reactive oxygen species, inflammatory and 
fibrogenic cytokines: TGF-β, PDGF, CTGF, FGF-2, IL-13 (Bondi, 2010; Chen, 2011, 
Strutz et al. 2000). These factors stimulate resident cells, where part of these cells undergo 
apoptosis (Song, 2007) and the other portion directly or indirectly contribute to the 
accumulation of interstitial myofibroblasts in the interstitium, around the blood vessels or 
in the glomerulus (Grande et al. 2015; Humphreys et al. 2010; LeBleu et al. 2013; Lin et al. 
2008; Wu et al. 2013). Myofibroblasts  are defined as cells with contractile properties that 
expresses α-SMA, type II intermediate filaments desmin and vimentin, and secrete proteins 
and ECM proteoglycans (fibrillar collagen type I, III, IV, fibronectin, laminin, perlecan and 
heparin). Although this is a simplified view of the processes that occurs during renal 
fibrogenesis, several of these steps occur simultaneously and can be much more complex. 
However, accumulation of myofibroblasts is a key event that persistently generates an 
increase in ECM deposits (Duffield et al. 2013, Duffield, 2014), which finally leads to 
disorganization of the kidney parenchyma and irreversible loss of kidney function. In this 
scenario, phenotypic transformation of resident and infiltrating cells in the kidney gives a 
clue about  the origins of myofibroblasts. Recent evidence (Humphreys et al. 2010; Lovisa 
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et al. 2015) showed that injured tubule epithelial cells acquire a mesenchymal-like 
phenotype, losing their properties to protect functional kidney parenchyma through cell 
cycle–dependent proliferation, dedifferentiation and repairing (Lovisa et al. 2015). 
Additionally, reprogramed epithelial cells acquire a profibrotic secretome that orchestrates 
transdifferentiation and recruitment of cells that contribute to accumulation of interstitial 
myofibroblasts (Grande et al. 2015; Wu et al. 2013; Lovisa et al. 2015; Grgic et al. 2012). 
Several sources of myofibroblasts have been identified by using cell-tracer fate in vivo in 
animal models of fibrosis. Among the identified contributors are local resident pericytes 
and fibroblasts (Chen et al.. 2011; Lin et al. 2008; Wu et al. 2013; Grgic et al. 2012; Smith 
et al. 2012), cells recruited from the bone marrow and from endothelial to mesenchymal 
cell transition (EndMT) (LeBleu et al. 2013) and macrophages via their transition to 
myofibroblasts in a process termed macrophage-myofibroblast transition (MMT) (Nikolic-
Paterson et al. 2011; Wang et al. 2016). Another pathological characteristic of CKD is 
glomerulosclerosis. Many studies have described that mesangial cells may acquire a 
myofibroblast-like phenotype that generates excessive ECM accumulation and increase 
TIMP (tissue inhibitors of metalloproteinases) levels (Riser et al. 2000; Bollineni and 
Reddi, 1993; Kagami et al. 1994; Ziyadeh et al. 2000). Recent evidence shows that loss of 
podocytes is a feature observed in numerous studies involving patients with CKD (Kim and 
Cheigh, 2001; Asanuma, 2015, Reiser and Sever, 2013). Injury and consequent depletion of 
podocytes using transgenic mice, provoked glomerulosclerosis with evident mesangial 
expansion, collapse of glomerular capillaries, and decreased kidney function (Wiggins et al. 
2005, Wharram et al. 2005). Finally, other authors indicated that podocyte injury led to a 
phenotypic change to myofibroblasts, expressing collagen1a1. This indicates that podocytes 
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and parietal epithelial cells also generate basal membrane thickening and capillary 
obstruction contributing to kidney fibrosis (Campanholle et al. 2013; Duffield, 2014). 
Interestingly, the first evidence that correlates adenosine with kidney fibrosis comes from 
studies performed by Ratech and col. (1985) in adenosine deaminase (ADA) deficient 
patients. Examination of renal tissue in cases of ADA deficiency showed mesangial 
sclerosis. Congenital ADA deficiency generates severe combined immune deficiency 
(SCID) (Booth and Gaspar, 2009) which is a consequence of impeded nucleotide 
metabolism containing adenine as nitrogenized base. The nucleotide dATP acts as an 
inhibitor of overall ribonucleotide reductase activity, affecting the immune system 
response. Furthermore, adenosine is also increased in this pathology. Recreation of 
adenosine imbalance in ada-/- KO mice leads to renal accumulation of collagen and 
proteinuria that can be blocked by using an adenosine receptor antagonist (Dai et al. 2011). 
The involvement of altered adenosine in fibrotic processes is not restricted to the kidney. 
ADA deficiency leads to the spontaneous development of pulmonary (Chunn et al. 2006) 
and skin (Fernandez et al. 2008) fibrosis in mice. In these models, increased collagen 
deposition was accompanied by increased levels of key fibrosis mediators, including TGF-
β, connective tissue growth factor and interleukin-13 (Ackley et al. 2003). In addition, 
pulmonary inflammation and fibrosis in wild-type mice subjected to bleomycin-induced 
lung injury also showed upregulated adenosine signaling (Sun et al. 2006). Another study 
showed induction of liver fibrosis in mice treated with CCl4, ethanol or TAA with 
extracellular adenosine levels two- to three-fold higher (Peng et al. 2008). Thus, gaining 
knowledge about the biochemical events that control local extracellular adenosine levels is 
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fundamental to the understanding of homeostatic kidney function and the pathogenic 
signaling pathways that mediate renal alterations. 
5. Adenosine and renal pathology 
5.1 Dysregulated adenosine levels 
Due to several limitations when quantifying adenosine in biological samples, such as its 
short half-life due to widely distributed metabolizing enzymes and the necessity of complex 
equipment such as mass spectrometers or high resolution chromatographers, clinical 
research that associates dysregulated adenosine levels with diseases is scarce. However, 
conclusive evidence collected from patients affected by diabetic CKD exists. Xia and col 
showed that disparate adenosine levels and the catabolic products inosine and uric acid, in 
the plasma of patients with diabetic nephropathy (DN) is concurrent with disease 
progression; meanwhile healthy and diabetic patients without renal repercussion have 
adenosine levels within the basal range (Xia et al. 2009, 2010). Further, using an integrated 
biomarker system to find a predictor of diabetic nephropathy in humans, it was found that 
the plasmatic adenosine-derived metabolite inosine could be useful as a prognosis tool 
(Huang et al. 2013).  
Additionally, several animal models have been used to correlate dysregulated adenosine 
homeostasis with the CKD pathogenesis. Among these, experimental diabetes induced in 
murines recapitulates glomerular alterations and incipient stages of fibrotic activation of 
cells, while animals with unilateral ureteral obstruction, hypertension or infused Ang II 
resemble glomerular and tubulointerstitial alterations leading to fibrosis and loss of renal 
function. 
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Studies in animal models of diabetic kidney disease reproduced the observations found in 
diabetic nephropathy patients. Firstly, experiments in streptozotocin-induced diabetic rats 
indicated that adenosine levels were significantly increased in renal vein plasma (Angielski 
et al. 1989). Roa et al. (2009) using this same animal model showed that isolated glomeruli 
from diabetic rats contained significantly higher external adenosine compared to controls 
(37.4 ± 3.1 v/s 6.0 ± 0.6 nM, corrected per µg of total glomeruli protein). Further, it was 
recently demonstrated that renal injury progression in diabetic rats develops with increased 
adenosine levels, having a strong correlation with the profibrotic marker α-SMA 
(Kretschmar et al. 2016), meanwhile increased urinary adenosine excretion could be 
detected during early onset of kidney dysfunction (Oyarzún et al. 2016). These observations 
highlight the fact that locally generated adenosine contributes to setting the pathological 
milieu of CKD progression. The biochemical events associated with increased local 
adenosine generation in diabetic kidney disease models was recently elucidated. ENT1 and 
ENT2 activity was examined to define the mechanisms associated with changes in 
adenosine levels at the glomerulus (Roa et al. 2009; Quezada et al. 2013). At this 
compartment, sodium-independent uptake activity was significantly decreased in diabetic 
rat glomeruli, in particular ENT1 activity was inhibited to 50%; these being the main 
engines for increasing extracellular adenosine accumulation that drives diabetic 
glomerulopathy (Roa et al. 2009). Recent evidence demonstrated inhibition of ENT1 
activity in the proximal tubules of rat diabetic kidney (Kretschmar et al. 2016), thus 
probably also contributing to increased external adenosine. Indeed, in ent1-/- mice or 
animals with pharmacologically inhibited ENT activity, the levels of interstitial and 
plasmatic adenosine were elevated (Li et al. 2013), highlighting the critical role of ENTs in 
adenosine homeostasis. This is of a major relevance because histological examination of 
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ent1-/- mice revealed increased interstitial collagen deposition and α-SMA in the kidney 
(Guillén-Gómez et al. 2012; Kretschmar et al. 2016). Some studies indicated that insulin 
and elevated glucose levels can regulate ENT activity in some cell types (Sakowicz et al. 
2004; Pawelczyk et al. 2003; Muñoz et al. 2006; Westermeier et al. 2011). There is strong 
evidence of the inhibitory effect of high glucose concentration on ENT1 and ENT2 activity 
in human endothelial cells and murine lymphocytes and podocytes (Sakowicz et al. 2004; 
Pawelczyk et al. 2003; Muñoz et al. 2006; Westermeier et al. 2011; Karczewska et al. 
2011). Some studies have identified the effect of insulin on restoring decreased nucleoside 
uptake activity. Recovery of basal adenosine extracellular levels in glomeruli exposed to 
high glucose, which have increased nucleoside accumulation, was attained by the addition 
of insulin via upregulation of ENT2 activity; suggesting that this transporter is a target of 
insulin in the kidney (Alarcón et al. 2015). This opposing modulation of ENT activity by 
glucose and insulin may allow maintenance of homeostatic adenosine levels during 
fluctuating physiological conditions. The impact of insulin on controlling renal cell 
function is of great interest. In fact, mice with podocyte-targeted deletion of the insulin 
receptor develop significant albuminuria together with histological features that recapitulate 
diabetic nephropathy (Welsh, 2010). Importantly, insulin resistance and poor glycemic 
control is present in both type 1 and type 2 diabetic patients, being a risk factor for the 
development of diabetic kidney disease (Ekstrand et al. 1998; Groop et al. 1993). Mima et 
al. (2011) analyzed both a type 1 diabetes model, generated by STZ treatment, and a type 2 
diabetes model, using the Zucker fatty strain, and observed a loss of insulin signaling in the 
kidney, suggesting that renal cells are susceptible to developing insulin resistance. Similar 
findings were described in podocytes (Tejada et al. 2008). We also recently demonstrated 
downregulation of the insulin receptor protein in kidney cortex from STZ induced diabetic 
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rats and diabetic patients (Gatica et al. 2013). Thus, lack of insulin responsiveness may 
permit kidney injury progression even when hormonal replacement therapy is performed. 
Also, this condition may affect adenosine handling by downregulating nucleoside uptake 
and leading to chronically increased levels of adenosine.  
In regards to adenosine metabolizing enzyme activity in diabetic CKD, information is 
available only from experimental models. In STZ-diabetic rats slight changes in 5’-
ectonucleotidase activity were observed in glomeruli (Roa et al. 2009), however a 
significant increase was also observed in the proximal tubules of diabetic rats (Oyarzún et 
al. 2015), indicating that compartmentalized extracellular adenosine generation may be 
differentially regulated. Interestingly, Oyarzún et al. (2015) demonstrated that AMPase 
activity mediated by 5’-ectonucleotidase, CD73, was increased during early diabetic renal 
injury. Since CD73 activity can be measured in urine, its use as a clinical tool for 
evaluating diabetic renal alterations affecting proximal tubules was proposed by the authors 
(Oyarzún et al. 2015). Studies of tubular damage biomarkers, such as KIM-I, NGAL, L-
FABP and Cystatin C are inconsistent, with larger studies in humans showing no additional 
value to traditional prediction models (Lim, 2014). Thus CD73 would be useful as a marker 
of CKD progression in the clinic. Other studies on adenosine metabolizing enzymes found 
that the expression of ecto-adenosine kinase (adenosine → AMP) was significantly lower in 
diabetic rat kidney (Pawelczyk et al. 2000; Sakowicz and Pawelczyk, 2002). 
Using different experimental approaches, it was suggested that increased adenosine and 
signaling is a common event in the pathogenesis of non-diabetic chronic kidney disease 
(Dai et al. 2011). Such is the case of renal fibrosis in mice generated by Ang II infusion and 
unilateral ureteral obstruction (UUO) (Dai et al. 2011; Lee et al. 2013). Also, Dai et al. 
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(2011) observed development of renal fibrosis in ada-/- animals. Whereas failed adenosine 
uptake due to insulin deficiency was observed in the diabetic model, however the 
mechanism leading to chronically high adenosine levels in these other CKD models is 
unknown. Genetic and pharmacological studies in mice revealed that CD73-mediated 
excess renal adenosine activates the A2B receptor and signaling, contributing to Ang II-
induced hypertension (Zhang et al. 2013). Also, CD73 and adenosine A2B receptor levels 
were significantly increased in the kidneys of human CKD patients compared with normal 
individuals and were further elevated in hypertensive CKD (Zhang et al. 2013). Thus, 
altered adenosine handling by cells or extracellular generation may contribute to chronic 
adenosine levels in CKD. In turn, future research should focus on establishing the 
alterations that occur to cellular functions mediated by adenosine and its receptors. 
5.2 Pathogenic functions of adenosine receptors in CKD 
In addition to the physiological functions attributed to adenosine receptors described in 
section 3, some of these receptors are linked to both protective and deleterious effects on 
kidney cells and renal function. Using pharmacological approaches and genetic deletion of 
receptors, the involvement of adenosine in acute and CKD was identified. As depicted in 
Table 2, the protective role of A1 and A2A receptor subtypes signaling was recognized by 
using the renal ischemia and reperfusion model where neutrophils infiltration and necrosis 
of proximal tubules was reduced. These findings could be applied to the creating of new 
therapies for acute renal disease.   
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The involvement of adenosine receptors in CKD (see Table 2) will be discussed with an 
emphasis on fibrotic process. Evidence indicates that the adenosine A2A receptor has a 
protective effect during podocyte injury, which was evaluated using toxicity assays in cells 
in vitro and by inhibiting monocyte/macrophage adhesion to endothelium in an 
experimental model of diabetic kidney disease (Persson et al. 2015; Awad et al. 2006, 
2008). However, how this protection is overwhelmed in CKD and is poorly understood. 
Apparently, adenosine signaling properties may be altered by the chronic increase of ligand 
due to the different pharmacological characteristics of the receptors, thus effecting different 
cellular responses (Fredholm et al. 2011; Roberts et al. 2014). Also, adenosine receptors 
may change their number and distribution during CKD. Analysis of the distribution and 
abundance of adenosine receptors in the human kidney and changes during diabetic CKD 
are underway. The distribution and abundance of A1, A2B and A3 receptors in the healthy 
kidney and in the kidney of diabetic nephropathy patients is shown in Figure 1. 
Histochemistry analysis shows changes in the expression of the adenosine receptors with 
the progression of the disease. There is evident loss of A1 receptor at the glomerulus, with 
increased staining at the tubules. One of the most noticeable alterations in the diabetic CKD 
was A2B receptor expression induced at the glomerular cells and increased abundance at the 
tubules. Interestingly, A2B receptor expression in non-diabetic CKD exhibited a similar 
upregulated pattern (Zhang et al. 2013). For the A3 receptor the most remarkable feature 
was receptor distribution at the tubules and interstitium during the advanced state of the 
diabetic kidney disease, which was recently recognized by Kretschmar et al. (2016). 
Overall, it is expected that these receptor distribution patterns contribute to their correlation 
with functional consequences at the cellular level. Indeed, the induction of the glomerular 
A2B receptor can be linked to increased TGF-β release and VEGF overproduction at the 
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glomerulus as previously described in the pathogenesis of diabetic renal injury in rats 
(Valladares et al. 2008; Roa et al. 2009; Cárdenas et al. 2013). Several groups have 
reinforced the probable pathogenic role of the adenosine A2B receptor, showing that this 
receptor subtype directs processes associated with CKD progression such as unbalance of 
the VEGF-NO axis and endothelin-1 induction in a hypoxia-inducible factor-α–dependent 
manner (Wilkinson et al. 2016; Patel et al. 2014; Zhang et al. 2013). Remarkably, a strong 
association between A2B receptor and renal fibrosis has been observed. Dai et al. (2011) 
demonstrated that development of renal fibrosis generated in all three models, ada-/- mice, 
Ang II infused animals and ureteral unilateral obstructed (UUO) animals, can be avoided 
when using an A2B receptor antagonist. A2B receptor mediated renal fibrosis was related to 
interleukin-6 induction (Dai et al. 2011). Additionally, a role for the A2B receptor in renal 
fibrosis could come from its capacity to mediate profibrotic activation of renal fibroblasts 
(Wilkinson et al. 2016). Cardenas et al. (2013) observed decreased induction of α-SMA in 
diabetic rats with pharmacological antagonism of the A2B receptor, probably resulting from 
attenuated profibrotic activation of resident or infiltrating cells. Complementary pathogenic 
effects were attributed to adenosine signaling via the adenosine A3 receptor in renal 
fibrosis. Signaling via A3 receptor is involved in the transition of tubular epithelial cells to a 
mesenchymal-like phenotype that leads to tubulointerstitial parenchyma remodeling and 
extracellular matrix deposition as described in section 4 (Kretschmar et al. 2016; Lee et al. 
2013). Interestingly, these studies suggest crosstalk between the A3 receptor and TGF-β 
fibrotic cascade in proximal tubule cells (Kretschmar et al. 2016; Lee et al. 2013). 
Furthermore, TGF-β induced CD73 in these cells (Oyarzún et al. 2015) reinforcing a 
positive feedback mechanism for directing kidney fibrosis. In vivo antagonism of the A3 
receptor attenuated fibrosis markers in diabetic rats and fibrosis in UUO animals 
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(Kretschmar et al. 2016; Lee et al. 2013). Thus common mechanisms of renal fibrosis 
pathogenesis in diabetic and non-diabetic CKD can be interfered through adenosine 
receptor antagonism. 
Several questions have arisen about the role of adenosine due to alterations in receptor 
profiles in diabetic and non-diabetic CKD. One of these refers to the mechanisms 
associated with A2B receptor induction or A3 receptor distribution in the kidney. Studies 
have demonstrated induction of A2B receptor mediated by the proinflammatory mediator 
TNF-α and hypoxia (Kolachala et al. 2010; St Hilaire et al. 2008; Yang et al. 2010; 
Koeppen et al. 2011). Interestingly these two factors are associated with CKD progression 
(Carrero et al. 2009; Fu et al. 2016). Ang II may also mediate A2B receptor induction (Dai et 
al. 2011). Thus a major task will be to solve the way that A2B receptor, with the lowest 
ligand affinity, may be upregulated concurrently with increased adenosine. Another 
interesting aspect is the tubulointerstitial distribution of the A3 receptor in diabetic CKD, 
resembling the myofibroblast pattern in renal fibrosis. Since the A3 receptor is also 
expressed in bone marrow derived cells (Haskó et al. 2008), the expression pattern in 
diabetic CKD could represent a pool of myofibroblasts from non-resident cells. Thus, 
contribution of this receptor subtype to myofibroblast generation or maintenance must be 
solved to be able to understand adenosine signaling integrated into the fibrotic process.   
6. Concluding remarks 
- One of the most astounding characteristics in experimental models of chronic renal 
disease of diabetic and non-diabetic origin is the increase in extracellular adenosine and of 
its catabolic products, which indicates that the pathogenesis of these renal conditions is 
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from a common axis. In humans, clinical studies confirm this characteristic in patients 
affected by diabetic nephropathy.  
- The biochemical mechanisms associated with increased adenosine levels involve both 
higher ectonucleotidase activity, which degrades precursor nucleotides, and lower 
extracellular adenosine uptake through equilibrative nucleoside transporter systems; 
although the series of events that underlie these alterations are unknown. In diabetes, 
metabolic and hormonal unbalance may influence lower ENT activity. 
- Cell signaling properties are altered due to a chronic increase of adenosine. Even more, 
changes in the amount and distribution of the adenosine receptors in chronic renal disease 
of diabetic and non-diabetic origin have been described. 
- The A2B and A3 adenosine receptors emerge as possible targets for pharmacological 
intervention due to their role in the development of renal fibrosis during chronic renal 
disease. However, the intervention possibilities are still limited. The development of a 
clinically useful A2B receptor selective antagonist is underway for the treatment of asthma 
and pulmonary disease. In fact, CVT-6883 has progressed to phase I clinical studies in 
humans, however it still requires further research. In the case of A3 receptor antagonists 
only preclinical studies has been performed. Some of the antagonists may be selected for 
clinical phase studies based on their pharmacological and chemical properties (Baraldi et al. 
2012). Interestingly, continuous administration of adenosine deaminase (ADA) decreased 
adenosine levels and precluded CKD in some animal models. Further, ADA replacement 
therapy is an effective therapy for ADA deficient patients (Booth and Gaspar, 2009; Wen et 
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al. 2010), although the cost of this product and its limitations in immune competent patients 
limits its implementation in the CKD population.  
- Further researches to resolve how the chronic adenosine cascade is founded to trigger 
pathogenic effects leading to CKD are underway. Also, validation of clinical tools that 
detect induction of the adenosine axis in CKD are needed. Measuring CD73 activity in the 
urine of at risk patients may be useful for detecting CKD, in addition to current standard 
procedures. This analysis will provide improved knowledge about the pathological 
processes that occur in human CKD and will help us observe when interception of 
adenosine signaling might be useful for opportune intervention. 
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Legend of the Figures 
Figure 1. Adenosine metabolism and cellular effects in the kidney. A. Homeostatic 
extracellular adenosine levels are generated from hydrolysis of the precursor nucleotides 
ATP and cAMP which are released by kidney cells. ATP is metabolized to AMP by the cell 
surface enzyme ecto-nucleoside triphosphate diphosphohydrolase 1 (ENTPD1 or CD39) 
and then to adenosine by ecto-5′-nucleotidase (NT5E or CD73). Extracellular cAMP is the 
substrate of phosphodiesterase (PDE) and consecutively AMP is dephosphorylated by 
CD73 to generate adenosine. The mechanisms involved in cell-mediated release of 
precursor nucleotides may include nucleotide permeable channels or extrusion mediated by 
vesicles, but this remains to be determined in kidney compartments. Intracellularly, 
adenosine is produced from S-adenosylhomocysteine (SAH) and converted to AMP by 
adenosine kinase (AK) or metabolized by the salvage pathway (SP) of purine nucleosides 
and nucleobases. The Equilibrative Nucleoside Transporters (NT) balances extracellular 
levels of the nucleoside and adenosine in the cells. In addition NT activity may be 
decreased to mediate extracellular accumulation of adenosine. B. Finely regulated 
extracellular levels of adenosine signal through four G-protein-coupled receptors A1, A2A, 
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A2B, and A3 in the healthy kidney to mediate physiological tasks such as tubuloglomerular 
feedback (TGF), renin release and ions balance. In contrast, chronic kidney disease models 
show persistently high levels of adenosine thus affecting cellular functions. The most 
remarkable consequences of unbalanced adenosine signaling in diabetic and non-diabetic 
CKD are glomerulopathy and renal fibrosis. 
Figure 2. Distribution of adenosine receptors in human diabetic CKD. 
Immunohistochemical detection of A1, A2B and A3 adenosine receptors (AR) in human 
kidney sections from non-diabetic normal tissue and biopsies from diabetic nephropathy 
patients. In the glomerular compartment there is evident induction of the A2B receptor 
subtype in diabetic CKD. Further, A3 receptor distribution to the tubulointerstitium was 
observed in advanced stages of diabetic nephropathy. The A1 receptor subtype was 
decreased in glomeruli but increased in tubular epithelial cells as the disease progresses. 
Selected images show representative progressive stages of renal injury probed by the 
content of α-smooth muscle actin (α-SMA) and pathological analysis. Original 
magnification 200x. Scale bars 50µm. 
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Table 1. Adenosine receptor distribution in the kidney 
Adenosine receptor subtype 
and localization 
Specie/Cell culture Method References 
 
Adenosine A1 receptor 
   
Podocytes and distal 
convoluted tubules 
 
Rat Immunohistochemistry Pawelczyk et al., 2005 
Isolated kidney glomeruli and 
podocytes 
 
Rat/cultured podocytes RT-PCR Valladares et al., 2008 
Thin limbs of Henle, 
collecting duct system and to a 
lesser extent in the medullary 
thick ascending limb. 
Mouse/rat RT-PRC Vitzthum et al., 2004 
 
Microdissected afferent 
arteriole  
 
Mouse 
 
RT-PCR 
 
Lu et al., 2015 
     
Microdissected efferent 
arteriole 
Mouse RT-PCR Al-Mashhadi et al., 2009 
 
Juxtaglomerular cells Primary cultures Mouse Immunolabeling/confocal 
microscopy/RT-PCR 
Ortiz-Capisano et., 2013 
 
Mesangial cells 
 
SV40 transformed mouse 
mesangial cell line 
 
RT-PCR 
 
Zhao et al., 2002 
Proximal tubule cells Human papillomavirus 16 
(HPV-16) transformed HK-2 
cells 
Real time RT-PCR Tang and  Zhou, 2003 
Adenosine A2A receptor    
Glomeruli 
 
Mouse/Rat RT-PCR Vitzthum et al., 2004 
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Conditionally immortalized 
podocyte cell line 
 
Mouse RT-PCR/ 
Immunocytochemistry 
Awad et al., 2008 
Juxtaglomerular cells 
 
Primary cultures of isolated 
mouse juxtaglomerular cells. 
RT-PCR Ortiz-Capisano et al., 
2013 
Juxtamedullary afferent 
arterioles 
Rat In vitro blood-perfused 
juxtamedullary nephron 
technique combined with 
videomicroscopy.(Functio
nal assay) 
Feng and Navar, 2010 
Microdissected efferent 
arterioles 
Mouse RT-PCR Al-Mashhadi et al., 2009 
 
Proximal tubule cells Human papillomavirus 16 
(HPV-16) transformed HK-2 
cells 
Real time RT-PCR Tang and Zhou, 2003 
Adenosine A2B receptor    
Cortical thick ascending limb 
of Henle and in the distal 
convoluted tubule 
 
Mouse /rat RT-PCR Vitzthum et al., 2004 
Glomeruli and tubules 
 
Human Immunohistochemistry Zhang et al., 2013 
Juxtaglomerular cells Mouse Primary cultures of 
isolated mouse 
juxtaglomerular cells/RT-
PCR 
Ortiz-Capisano et al., 
2013 
Juxtamedullary afferent 
arterioles. 
Rat In vitro blood-perfused 
juxtamedullary nephron 
technique combined with 
videomicroscopy. 
Feng and Navar, 2010 
Renal inner medullary 
collecting duct 
 
Immortalized cell line 
mIMCD-K2/murine model. 
Western Rajagopal and Pao, 2010 
Isolated glomeruli and 
podocytes 
Rat/cultured podocytes RT-PCR/ 
Immunohistochemistry 
Valladares et al., 2008 
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Microdissected efferent 
arterioles. 
Mice RT-PCR Al-Mashhadi et al., 2009 
 
Mesangial cells 
 
 
SV40 transformed mouse 
mesangial cell line from 
adult male Wistar-Kyoto rats 
RT-PCR/Inhibition assay 
with MRS1754 
Zhao et al., 2002 
Jackson et al., 2010; 
Jackson et al., 2011 
Fibroblast  
 
Rat cell line NRK-49F RT-PCR Wilkinson et al., 2016 
Initial segment of the inner 
medullary collecting duct 
Murine cell line mIMCD-K2  Western blotting Rajagopal et al., 2010 
Adenosine A3 receptor    
Microdissected isolated 
afferent arteriole 
Mouse RT-PCR  Lu et al., 2015 
 
Microdissected efferent 
arterioles 
 
Mouse 
 
RT-PCR 
 
Al-Mashhadi et al., 2009 
 
 
Mesangial cells 
 
SV40 transformed mouse 
mesangial cell line 
 
RT-PCR 
 
Zhao et al., 2002 
    
Glomeruli and tubules 
 
Human Immunohistochemistry Kretschmar et al. 2016 
Proximal tubules Human papillomavirus 16 
(HPV-16) transformed HK-2 
cells and rat purified 
proximal tubules 
Western blot Kretschmar et al. 2016 
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Table 2. Involvement of adenosine receptors in acute and chronic kidney diseases 
Adenosine 
receptor 
Model of 
kidney injury 
Interventional 
strategy 
Effect Reference 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A1 
Ischemia and 
reperfusion 
 
CCPA agonist  
 
Restores renal function, attenuates 
the expression of inflammation 
markers ICAM-1, IL-1β and TNF-α, 
necrosis and apoptosis 
Lee et al. 2004a 
Ischemia and 
reperfusion 
DPCPX 
antagonist  
Increases renal dysfunction, tubular 
necrosis, inflammation and apoptosis 
Lee et al. 2004a 
Ischemia and 
reperfusion 
 
 A1AR-/- mice 
 
Increases the expression of 
inflammation markers ICAM-1, IL-
1β and TNF-α. Augments neutrophils 
infiltration 
Lee et al. 2004b 
 
Ischemia and 
reperfusion 
CCPA agonist  
 
Reduces necrosis in proximal tubules, 
neutrophils infiltration, inflammation 
and apoptosis in IL-11 receptor KO 
mice 
Kim et al. 2013 
Ischemia and 
reperfusion 
 
DPCPX 
antagonist  
Enhances lymphocyte infiltration and 
TNF-α production 
Najafi et al. 2016 
Alloxan-
induced 
diabetes  
A1AR-/- mice Increases glomerular filtration rate Sällström et al. 
2007 
Diabetic 
nephropathy 
A1AR-/- mice Increases renal injury and glomerular 
filtration rate  
Faulhaber-Walter et 
al. 2008 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A2A 
Ischemia and 
reperfusion 
DWH146e 
antagonist 
Inhibits inflammation, reduces renal 
damage 
Okusa et al. 1999 
Ischemia and 
reperfusion 
ZM241385 
antagonist 
Blockades the renoprotector effects 
of DWH146e   
Okusa et al. 1999 
Ischemia and 
reperfusion 
DWH 146e 
agonist 
Reduces neutrophil infiltration in 
renal cortex and medulla. Decreases 
ICAM-1 expression 
Okusa et al. 2000 
Diabetic 
nephropathy 
ATL146e o 
ATL313 
agonists 
Attenuates the fibrotic marker 
fibronectin and reduces macrophages 
infiltration in glomeruli 
Awad et al. 2006 
Glomerulonep
hritis 
CGS21680 
agonist 
Reduces macrophages infiltration and 
collagen type I, II and IV deposition.  
Restores expression of E-cadherin 
and decreases the expression of α-
García et al. 2011 
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SMA in interstitium and the 
glomerulus 
unilateral 
ureteral 
obstruction 
A2AAR-/- mice Increases progression of 
tubulointerstitial fibrosis 
Xiao et al. 2013 
unilateral 
ureteral 
obstruction 
CGS21680 
agonist 
Significantly reduces collagen 
deposition, TGF-β and lymphocytes 
T CD4+ infiltration  
Xiao et al. 2013 
Diabetic 
nephropathy 
 
CGS21680 
agonist 
 
Prevents glomerular damage by 
inhibition of the inflammatory 
pathway. Reverses proteinuria and 
decreases urinary excretion of TNF-
α. 
Persson et al. 2015 
 
 
 
 
 
 
 
 
 
 
 
A2B 
unilateral 
ureteral 
obstruction 
A2BAR-/- mice Attenuates IL-6 induction Dai et al. 2011 
Diabetic 
nephropathy 
MRS1754 
antagonist 
Restores nephrin and attenuates 
VEGF expression and α-SMA 
induction in glomeruli 
Cárdenas el al. 
2013 
Diabetic 
nephropathy 
MRS1754 
antagonist 
Reduces  VEGF expression and 
restores nitrite levels in the kidney 
tissue 
Patel et al. 2014 
Diabetic 
nephropathy 
A2BAR-/- mice  Increases glomerular filtration rate 
and albumin excretion 
Tak et al. 2014 
Cyclosporine 
A-induced 
Nephropathy  
MRS1754 
antagonist 
Reverses the increase of VEGF 
induced by the non-selective agonist 
NECA of adenosine receptors  
Patel et al. 2015 
 
 
 
 
 
 
 
 
A3 
Ischemia and 
reperfusion 
A3AR-/- mice Attenuates renal injury and restores 
renal function 
Lee et al. 2003 
Ischemia and 
reperfusion 
MECA agonist Favors renal damage Lee et al. 2003 
unilateral 
ureteral 
obstruction 
LJ1888 
antagonist 
Inhibits the expression of fibronectin 
and collagen I. Reduces interstitial 
collagen  
Lee et al. 2013 
Diabetic 
nephropathy 
MRS1220 
antagonist  
Reduces α-SMA Kretschmar et al. 
2016 
Adriamycin-
induced 
LJ1888 
antagonist  
Restores nephrin and decreases 
collagen type IV, NF-κB, NOX4, 
Min et al. 2016 
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nephropathy TLR4, TNFα, IL-1β and IFN-γ 
expression 
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